Basic Information
Beromun
Regulatory Information
EMEA/H/C/000206
April 12, 1999
15
January 10, 2022
Company Information
Luxembourg
2, Rue Albert 1 er L-1117 Luxembourg
Belpharma Sa
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated-limb perfusion (ILP).
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).